Warhead Library - PROTAC® / BOC Sciences

Structure	Catalog	Product Name	CAS	Molecular Formula	Molecular Weight	Target	Inquiry
	BPL-100001	MI-1242	2300981-48-8	C31H29Cl2FN4O3	595.50	MDM2	Inquiry
	BPL-100002	MI-1061	1410737-34-6	C30H26Cl2FN3O4	582.45	MDM2	Inquiry
Description: MI-1061 is a potent and orally bioavailable MDM2 (MDM2-p53 interaction) inhibitor (IC50 = 4.4 nM; Ki = 0.16 nM). It potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice.
	BPL-100006	2-chloro-4-[4-(4-fluorobenzyl)-3,5-dimethyl-1H-pyrazol-1-yl]benzonitrile	1189135-20-3	C19H15ClFN3	339.80	AR	Inquiry
	BPL-100007	HJB97	2093391-24-1	C26H28N8O3	500.55	BRD2 BRD3 BRD4	Inquiry
Description: HJB97 is used for the design of potential PROTAC BET degrader. It also has antitumor activity.
	BPL-100008	7-(3,5-dimethyl-1,2-oxazol-4-yl)-6-methoxy-N-methyl-9H-pyrimido[4,5-b]indole-2-carboxamide	2093392-56-2	C18H17N5O3	351.37	BRD2 BRD3 BRD4	Inquiry
	BPL-100009	MZ-242	1862238-01-4	C24H27N7O3S2	525.65	SIRT2	Inquiry
Description: MZ-242 is a potent and selective Sirt2 inhibitor.
	BPL-100010	QCA276	2126819-40-5	C22H19N5OS	401.49	BRD2 BRD3 BRD4	Inquiry
	BPL-100011	N-piperidine Ibrutinib	330785-90-5	C22H22N6O	386.45	BTK	Inquiry
Description: N-piperidine Ibrutinib, a reversible Ibrutinib derivative, acts as a potent BTK inhibitor with IC50s of 51.0 nM for WT BTK and 30.7 nM for C481S BTK. It serves as a BTK ligand in the synthesis of PROTACs, such as SJF620. SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM.
	BPL-100012	(E)-3-[4-[[2,4-bis(trifluoromethyl)phenyl]methoxy]-3-methoxyphenyl]-2-cyanoprop-2-enamide	2306388-59-8	C20H14F6N2O3	444.33	ERRalpha	Inquiry
	BPL-100013	1-[(3R)-1-acetylpiperidin-3-yl]-5-amino-3-[4-(2,4-difluorophenoxy)phenyl]pyrazole-4-carboxamide	2250080-62-5	C23H23F2N5O3	455.47	BTK	Inquiry
	BPL-100014	N'-hydroxy-N-[(E)-(4-methoxyphenyl)methylideneamino]octanediamide	1977496-14-2	C16H23N3O4	321.37	HDAC6	Inquiry
	BPL-100015	(13R)-4-chloro-21-methyl-11-(4-methylpentanoyl)-15,18-dioxa-2,6,8,11,21,28-hexazapentacyclo[17.7.1.1^3,7.0^8,13.0^20,25]octacosa-1(26),3(28),4,6,19(27),20(25)-hexaen-22-one	2257479-53-9	C27H35ClN6O4	543.07	BCL6	Inquiry
	BPL-100016	GSK4028	2079886-19-2	C17H21BrN4O	377.28	PCAF	Inquiry
Description: GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC50 of GSK4028 is 4.9 in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.
	BPL-100017	N-(5-cyclobutyl-1H-pyrazol-3-yl)-2-(4-methoxyphenyl)acetamide	2118356-94-6	C16H19N3O2	285.34	CDK9	Inquiry
	BPL-100018	N-[6-(tert-Butylsulfonyl)-7-methoxy-4-quinolyl]benzo[d]thiazol-5-amine	1398054-21-1	C21H21N3O3S2	427.53	RIPK2	Inquiry
	BPL-100019	N-[2-(2-fluoro-4-iodoanilino)-1,5-dimethyl-6-oxopyridin-3-yl]benzenesulfonamide	1258882-61-9	C19H17FIN3O3S	513.33	MEK1 MEK2	Inquiry
	BPL-100020	SI-109	2429877-30-3	C40H44F2N7O9P	835.79	STAT3	Inquiry
Description: SI-109 is a potent STAT3 SH2 domain inhibitor (Ki=9 nM) with antitumor activity. SI-109 and an analog of CRBN ligand lenalidomide have been used to design PROTAC STAT3 degrader SD-36.
	BPL-100021	[[2-[[(5S,8S,10aR)-3-acetyl-8-[[(2S)-5-amino-1-(benzylamino)-1,5-dioxopentan-2-yl]carbamoyl]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocin-5-yl]carbamoyl]-1H-indol-5-yl]-difluoromethyl]phosphonic acid	2429877-24-5	C34H40F2N7O9P	759.70	STAT3	Inquiry